Functional relevance of antiemetic control: Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant

A. R. Martin, A. D. Carides, J. D. Pearson, K. Horgan, M. Elmer, C. Schmidt, B. Cai, S. P. Chawla, S. M. Grunberg

Research output: Contribution to journalArticlepeer-review

Abstract

Little information exists on the functional impact of effective antiemetic protection. In the present study, the Functional Living Index - Emesis (FLIE), was used to assess patient-reported impact of chemotherapy-induced nausea and vomiting (CINV) after administration of a new NK-1 receptor antagonist (aprepitant). Cisplatin-treated patients in a double-blind randomised trial received either aprepitant+dexamethasone+ondansetron on day 1 and aprepitant+dexamethasone on days 2-5 or standard antiemetic therapy (dexamethasone and ondansetron on day 1 and dexamethasone on days 2-5). Emetic events, nausea ratings and rescue medications were recorded in a 5-day diary and the FLIE was completed on day 6. Compared with standard therapy, significantly more patients treated with the high dose aprepitant regimen achieved a Complete Response (71 vs 44%, P<0.001) and also reported no impact on daily life as indicated by the FLIE total score (84 vs 66%, P<0.01). Use of the FLIE demonstrated that improved control of emesis was highly effective in reducing the impact of CINV on patients' daily lives.

Original languageEnglish (US)
Pages (from-to)1395-1401
Number of pages7
JournalEuropean Journal of Cancer
Volume39
Issue number10
DOIs
StatePublished - Jul 2003

Keywords

  • Antiemetics
  • FLIE
  • Nausea
  • Patient-reported outcomes
  • Quality of life
  • Vomiting

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Functional relevance of antiemetic control: Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant'. Together they form a unique fingerprint.

Cite this